Journal article
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials
Abstract
BACKGROUND: Despite several investigations, second malignancy risks (SMR) following radiotherapy alone (RT), chemotherapy alone (CT) and combined chemoradiotherapy (CRT) for Hodgkin's lymphoma (HL) remain controversial.
PATIENTS AND METHODS: We sought individual patient data from randomised trials comparing RT versus CRT, CT versus CRT, RT versus CT or involved-field (IF) versus extended-field (EF) RT for untreated HL. Overall SMR (including …
Authors
Franklin J; Pluetschow A; Paus M; Specht L; Anselmo A-P; Aviles A; Biti G; Bogatyreva T; Bonadonna G; Brillant C
Journal
Annals of Oncology, Vol. 17, No. 12, pp. 1749–1760
Publisher
Elsevier
Publication Date
12 2006
DOI
10.1093/annonc/mdl302
ISSN
0923-7534